National Cancer Registry

Definition	A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives	- To measure cancer incidence - To describe cancer by time, place, persons and disease - To provide a national database for further epidemiological research
Case definition	Target cases are: - Incident cases by year of diagnosis - Malignant tumors confirmed by histopathology and/or hematology findings - Cancers of all sites
Sources of data	Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting). 1) The capture system: The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms: - Directly from their clinic; or - Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients 2) The recapture system: The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding	The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3). The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor. The structure is C##.# M####/##, where: - C##.# specifies the primary site - M#### specifies the histology - /## specifies the behavior and the grade of the tumor
Reporting form	NCR reporting form

ATC	Name	B/G	Ingredients	Dosage	Form	Price
B05D	CAPD/DPCA 3Solution for peritoneal dialysis	G	Sodium chloride - 5.786g/l, Sodium-(S)-lactate - 3.925g/l, Calcium chloride 2H2O - 0.2573g/l, Magnesium chloride, 6H2O - 0.1017g/l, Anhydrous glucose - 42.50g/l, Glucose monohydrate - 46.75g/l		Injectable solution	740,031 L.L
B05D	CAPD/DPCA 17Solution for peritoneal dialysis sleep safe	G	Sodium chloride - 5.786g/l, Sodium-(S)-lactate - 3.925g/l, Calcium chloride 2H2O - 0.1838g/l, Magnesium chloride, 6H2O - 0.1017g/l, Anhydrous glucose - 15g/l, Fructose , - up to 0.75g/l		Injectable solution	715,794 L.L
S01FA04	CICLOPLEGICEDOL	G	Cyclopentolate HCl - 10mg/ml	10mg/ml	Drops solution	459,594 L.L
B05D	CAPD/DPCA 19Solution for peritoneal dialysis sleep safe	G	Sodium chloride - 5.786g/l, Sodium-(S)-lactate - 3.925g/l, Calcium chloride 2H2O - 0.1838g/l, Magnesium chloride, 6H2O - 0.1017g/l, Anhydrous glucose - 22.73g/l, Fructose , - up to 1.1g/l		Injectable solution	715,794 L.L
N02BE51	COQUELUSEDAL PARACETAMOL	G	Paracetamol - 100mg, Grindelia extract - 10mg, Gelsenium extract - 5mg	100mg	Suppository	575,270 L.L
N02BE51	COQUELUSEDAL PARACETAMOL	G	Paracetamol - 250mg, Grindelia extract - 20mg, Gelsenium extract - 10mg	250mg	Suppository	611,224 L.L
B05XA01	CHLORURE DE POTASSIUM PROAMP	G	Potassium chloride - 0.0746g/ml	0.0746g/ml	Injectable concentrated solution	1,252,461 L.L
B05XA01	CHLORURE DE POTASSIUM RENAUDIN	G	Potassium chloride - 7.46g/100ml	7.46%	Injectable solution	385,683 L.L
R05	COQUELUSEDAL NOURRISSON	G	Grindelia extract - 10mg, Gelsenium extract - 5mg		Suppository	496,170 L.L
S01GX09	CONJYCLEAR	G	Olopatadine (HCl) - 0.1%	0.1%	Drops solution	510,660 L.L
H01BB03	CARBETOCINA GP-PHARM	G	Carbetocin - 100mcg	100mcg	Injectable solution	9,041,227 L.L
B05XA01	CHLORURE DE POTASSIUM RENAUDIN	G	Potassium chloride - 10g/100ml	10g/100ml	Injectable solution	360,150 L.L
R05	COQUELUSEDAL ENFANT	G	Grindelia extract - 20mg, Gelsenium extract - 10mg		Suppository	575,270 L.L
L01BC06	CAPECITABINE ACCORD	G	Capecitabine - 500mg	500mg	Tablet, film coated	10,908,012 L.L
L01BC06	CAPECITABINE BIOGARAN	G	Capecitabine - 500mg	500mg	Tablet, coated	12,123,049 L.L
C09DA03	CO-ANGINET	G	Valsartan - 160mg, Hydrochlorothiazide - 12.5mg		Tablet, film coated	544,256 L.L
L01BC06	CAPECITABINE GP PHARM	G	Capecitabine - 500mg	500mg	Tablet, film coated	8,869,508 L.L
C09DA03	CO-TABUVAN	G	Valsartan - 160mg, Hydrochlorothiazide - 12.5mg		Tablet, film coated	544,256 L.L
L01BC06	CAPECITABINE NEAPOLIS	G	Capecitabine - 500mg	500mg	Tablet, film coated	11,222,829 L.L
G01AA10	CLINDAMYCIN	G	Clindamycin - 100mg	100mg	Ovule	712,876 L.L
J02AC01	CANDIZOL	G	Fluconazole - 150mg	150mg	Capsule	385,235 L.L
L01BC06	CAPECITABINE SPC	G	Capecitabine - 500mg	500mg	Tablet, film coated	12,665,771 L.L
L01BC06	CAPEDA	G	Capecitabine - 500mg	500mg	Tablet, film coated	4,927,423 L.L
J01DD08	CEFIX	G	Cefixime (trihydrate) - 100mg/5ml	100mg/5ml	Powder for suspension	349,399 L.L
L01BC06	CAPECITABINE SPC	G	Capecitabine - 150mg	150mg	Tablet, film coated	4,094,240 L.L
S02AA15	CETRAXAL OTICO	G	Ciprofloxacine (HCl) - 3mg/ml	3mg/ml	Drops	821,088 L.L
G01AF02	CANAGYN	G	Clotrimazole - 100mg	100mg	Tablet	229,797 L.L
A11CC05	CHOLECALCIFEROL BIOGARAN	G	Vitamin D3 - 100,000UI/2ml	100,000UI	Solution	115,570 L.L
B05XA03	CHLORURE DE SODIUM 0.9 pour cent Renaudin	G	Sodium chloride - 0.9%	0.9%	Injectable solution	385,683 L.L
J01DD08	CEFIX	G	Cefixime (trihydrate) - 100mg/5ml	100mg/5ml	Powder for suspension	700,142 L.L

National Cancer Registry (NCR)